Design, Synthesis, Molecular Docking Study and Biological Evaluation of Novel γ-Carboline Derivatives of Latrepirdine (Dimebon) as Potent Anticancer Agents
Ramakrishna Voggu,
Arundhati Karmakar,
Venkat Swamy Puli,
V. Surendra Babu Damerla,
Padma Mogili,
P. Amaladass,
Sridhar Chidara,
Kalyan Kumar Pasunooti,
Sarika Gupta
Affiliations
Ramakrishna Voggu
Department of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India
Arundhati Karmakar
Molecular Science Laboratory, National Institute of Immunology, New Delhi 110067, India
Venkat Swamy Puli
Department of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India
V. Surendra Babu Damerla
Department of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India
Padma Mogili
Department of Engineering Chemistry, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India
P. Amaladass
Department of Chemistry, Madanapalle Institute of Technology & Science, Madanapalle 517325, Andhra Pradesh, India
Sridhar Chidara
Department of Medicinal Chemistry, Aragen Life Sciences Pvt. Ltd. (Formerly Known as GVK Biosciences Pvt. Ltd.), IDA, Nacharam, Hyderabad 500076, Telangana, India
Kalyan Kumar Pasunooti
ProSAM Bioscience Pvt. Ltd., Hyderabad 500049, Telangana, India
Sarika Gupta
Molecular Science Laboratory, National Institute of Immunology, New Delhi 110067, India
A series of novel γ-Carboline derivatives were designed and synthesized using the Suzuki coupling reaction to identify the leads for the activity against cancer. Interestingly, these compounds were tested for their anticancer activity against the cell lines, particularly human cancer cell lines MCF7 (breast), A549 (lung), SiHa (cervix), and Colo-205 (colon). Most of the γ-Carboline derivatives showed potent inhibitory activity in four cancer cell lines, according to in vitro anticancer activity screening. Two compounds, specifically LP-14 and LP-15, showed superior activity in cancer cell lines among the γ-Carboline derivatives from LP-1 to LP-16. Additionally, the compound LP-14, LP-15 and Etoposide carried out molecular docking studies on human topoisomerase II beta in complex with DNA and Etoposide (PDB ID: 3QX3). The docking studies’ results showed that the derivative LP-15 was strongly bound with the receptor amino acid residues, including Glu477 and DC8 compared with the marked drug Etoposide.